Key points from article :
Derm-Biome Pharmaceuticals in Vancouver is developing a new skincare treatment that focuses on the deeper causes of skin ageing, looking beyond surface wrinkles to the inflammation and cell damage that build up over time. Their researchers have been studying compounds that can calm inflammation, limit harmful bacteria on the skin, protect against oxidative stress, and encourage the skin to produce more collagen.
In early laboratory work, these compounds were applied to skin models and produced quick, visible improvements, as well as a delay in the kind of UV-related damage that normally leads to sagging and fine lines. Further testing is planned for the autumn using a UV-induced ageing model that imitates long-term sun exposure, allowing the team to see how well the lead compound can prevent or slow age-related changes at the cellular level.
The work has been supported by TransBIOtech, where investigator Frédéric Couture noted clear benefits in the preclinical studies, and CEO Gordon Eberwein stressed that the treatment aims to address the biological drivers of ageing rather than just its early outward signs. The update was shared through a Globe Newswire release at a time when interest in evidence-based skincare is growing alongside the expanding global anti-ageing market.
